Given that ARF6 can regulate both PI3K-AKT8 and BRAFV600E -MAPK signaling (Fig. 1) and apoptosis upon serum withdrawal (Fig. 3c–d), we asked if ARF6 supports the viability of BRAF-mutant human cancer cells grown in full serum. Here, BRAF is linked to cancer.